Radcliffe Capital Management’s NKGen Biotech, Inc. Warrants NKGNW Stock Holding History

Radcliffe Capital Management’s Portfolio NKGNW Stock Details NKGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-120,000	Closed	-$25.1K	–	495
2023 Q2	$25.1K	Hold	120,000	–	–	﹤0.01%	302
2023 Q1	$17.4K	Hold	120,000	–	–	﹤0.01%	449
2022 Q4	$1.19M	Hold	120,000	–	–	0.04%	620
2022 Q3	$1.17M	Hold	120,000	–	–	0.03%	855
2022 Q2	$1.17M	Hold	120,000	–	–	0.03%	906
2022 Q1	$1.17M	Hold	120,000	–	–	0.03%	894
2021 Q4	$1.16M	Hold	120,000	–	–	0.03%	779
2021 Q3	$1.16M	Buy	+120,000	New	+$150K	0.03%	666

Other funds holding NKGNW

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PSAMP

P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

Radcliffe Capital Management's NKGNW Position: Q3 2023 in Review

Radcliffe Capital Management sold out of NKGen Biotech, Inc. Warrants (NKGNW) in Q3 2023, closing a stake of 120,000 shares — an estimated $25.1K sold.

Radcliffe Capital Management first reported a position in NKGNW in Q3 2021 and held it in 8 quarters. The position peaked at $1.19M in Q4 2022. 21 funds tracked by Wall St. Rank hold NKGNW as of Q3 2023.

Radcliffe Capital Management reported no remaining NKGen Biotech, Inc. Warrants position as of Q3 2023 after selling out during the quarter.
Radcliffe Capital Management sold 120,000 NKGen Biotech, Inc. Warrants shares in Q3 2023, an estimated $25.1K.
Radcliffe Capital Management first reported a position in NKGen Biotech, Inc. Warrants in Q3 2021 and held it in 8 quarters.
Radcliffe Capital Management's NKGen Biotech, Inc. Warrants position peaked at $1.19M in Q4 2022.
21 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Warrants as of Q3 2023.

Based on Radcliffe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.